Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Philadelphia based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Brian Piper
Chief Financial Officer of Prelude Therapeutics
Brian Piper joined Medgenics as VP, Finance and Investor Relations in April 2014. Prior to joining Medgenics, Mr. Piper served as Senior Director, Strategic Investment Group (SIG), for Shire Pharmaceuticals, LLC from 2010 to 2013, as well as several different finance and business development roles with Shire over the past 13 years. Mr. Piper began his affiliation with Shire in 2002 as Director of Finance for Shire’s North American Development group in Rockville, MD. In 2004 he established Shire’s first US Investor Relations group, based out of Philadelphia. After three years running US Investor Relations, Mr. Piper transitioned to an alliance management role and spent two years overseas in Dublin, Ireland helping establish geographic expansion strategies. Prior to joining Shire, Mr. Piper held strategic planning roles for Celera Genomics, was Controller for a start-up Contract Research Organization, and worked as a program planner and financial analyst for Otsuka Pharmaceuticals, Inc. Mr. Piper received a B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.
Follow Brian Piper:
About Aevi Genomic Medicine, Prelude Therapeutics, Scorpion Therapeutics: Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.
Frank Ruffo
Co-Founder, Chief Financial Officer of Aclaris Therapeutics
Frank Ruffo co-founded Aclaris and has served as Chief Financial Officer since its inception in 2012. He is a senior financial executive with more than 20 years of biotech and specialty pharmaceutical management expertise in early stage through fully commercial operations. From 2014 to 2015, Frank served part time as a financial consultant at Ralexar Therapeutics, Inc. (formerly known as Alexar Therapeutics Inc.), a specialty dermatology company. Frank also served part time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from 2011 to 2014 and the Chief Financial Officer of BioLeap, Inc. from 2010 to 2013. Prior to joining Aclaris, Frank co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan in 2011. Prior to joining Vicept Therapeutics, from 1996 to 2008 he served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. Frank is a certified public accountant in Pennsylvania (inactive since 2008). He received his Bachelor of Science in business administration with a major in accounting from La Salle University.
Follow Frank Ruffo:
About Aclaris Therapeutics, Vicept Therapeutics: Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Maria Kraus
Chief Financial Officer of AES
Follow Maria Kraus:
About AES: AES provides clinical trial acceleration solutions for various medical sectors.
Joel Sussman
Chief Financial Officer of Immunome
Joel Sussman is a financial management consultant who serves in the capacity of CFO for early-stage companies including Garnet BioTherapeutics. His present and former clients include numerous venture capital-backed life sciences companies as well as companies in the fields of information technologies and services. Before beginning his consulting practice in 1995, he had fifteen years experience as Chief Financial Officer and/or Treasurer of public and private technology and healthcare companies. In 1997, he joined a client, CDNow, Inc., as CFO and took it public, resuming his consulting practice in 2001 after its sale to Bertelsmann AG. Mr. Sussman began his career as a banker and has an undergraduate degree from Yale University, an MBA degree from the Wharton School of the University of Pennsylvania, and is a licensed Certified Public Accountant in Pennsylvania.
Follow Joel Sussman:
About Galera Therapeutics, Immunome, PhaseBio Pharmaceuticals: Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery.
David Garrett
CFO of Dynacure
David Garrett joins Dynacure from Nabriva Therapeutics, Inc. where he held various roles including VP, Corporate Controller and Head of Investor Relations and Sr. Director, Business Planning and Analysis. At Nabriva, Mr. Garrett led all Wall-Street facing activities, completed over $150M in equity capital raises, and oversaw all SEC reporting and compliance functions. Mr. Garrett was also responsible for leading Nabriva’s redomicile from Austria to Ireland. Prior to Nabriva, Mr. Garrett held senior-level finance roles at Covis Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., and ViroPharma Incorporated and was a manager at KPMG, LLP. Mr. Garrett received an MBA and BS in Accountancy from Villanova University and is a Certified Public Accountant in Pennsylvania.
Follow David Garrett:
About Dynacure, iECURE: Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.
